Home
overview

SMi Group announces the 11th Annual RNA Therapeutics Conference in London on February 19th - 20th 2020.


The field of RNA therapeutics is rapidly expanding, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

The global antisense and RNA therapeutics market size is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025, when it is projected to reach $1.81 billion. RNA-based drugs, including short interfering RNAs and antisense oligonucleotides, are particularly promising examples of this newer class of biologics. For over two decades, researchers have been trying to overcome major challenges for utilizing such RNAs in a therapeutic context, including intracellular delivery, stability, and immune response activation. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.


This year, we will maintain our focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore we will, for the first time in the series, introduce a focus day on Oligonucletide Delivery Systems. Our main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. We will also cover a fair bit of regulation, such as continuing upon patenting novel products, release of new 2020 regulations in the clinical trials arena, as well as ensuring compliance. Finally, a significant section that tackles novel and emerging therapies as well as the latest research findings from academia will also be present in this year’s agenda.


Join us in February 2020, as SMi’s RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.
 

 

• Join us for a focus day to discuss the innovations in oligonucleotide delivery systems
• Explore the latest developments in RNA delivery agents and RNA-based therapeutics
• Learn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies
• Revisit the challenges for clinical translation of RNA-based therapeutics
• Evaluate the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing
• Gain an expert view on new and upcoming regulatory updates and industry implications
 

Key Job Titles include:

Research & Development Directors/Managers/Scientists
Heads of Clinical Development
Heads of Pre-Clinical Development
Head of RNA Biology
Head of RNA Formulation and Drug Delivery
Head of Pre-clinical R&D
Head of New Modalities
Head of Discovery
Senior Scientists
Chief Scientific Officers
Chief Medical Officers


Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.

Accanis Therapeutics; Advanced Cell Diagnostics – A Bio-Techne Brand; Aescap 2.0; Alnylam Pharmaceuticals UK & Ireland; AmpTec GmbH; Aseptic Technologies SA; AstraZeneca; Bachem AG; BianoGMP; BioNTech IMFS GmbH; BioNTech RNA Pharmaceuticals; Boehringer Ingelheim Pharma GmbH & Co. KG; Calithera Biosciences; CEPI - Coalition for Epimemic Prepardness Innovation; Chemgenes Corporation; Curevac Ag; Dicerna Therapeutics.; Duke University School of Medicine; Ethris GmbH; Exicure Inc.; F.Hoffmann-La Roche AG; GSK; Horizon Discovery; InteRNA Technologies BV; Intertek; Lipocalyx; MedImmune; MHRA; MiNA Therapeutics; N4 Pharma UK Limited; New England Biolabs; NHS Blood and Transplant Authority; Nitto Avecia; NOF Europe GmbH; Nouscom SRL; ProQR Therapeutics; RCSI; RCSI Royal College of Surgeons in Ireland,; RNA Medco; ROCHE; Roche Diagnostics Deutschland GmbH; Roche Innovation Center; Russell Publishing Ltd; Sanofi; Sanofi-Aventis Deutschland GmbH; Takeda Development Centre Europe Ltd.; TCR Solutions; The Italian Institute of Technology; The RNA Medicines Company; Thermo Fisher Scientific; University Medicine Mainz Hospital; University Of Portsmouth; University Of Surrey; Yuria Pharma;

Conference programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Delivery , BioNTech AG
View Bio

9:10 Current progress of RNA therapeutics and industry overview: setting the scene

Shalini  Andersson

Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
View Bio

• Revisiting the essential concepts behind RNA therapy
• A brief history of RNA therapeutics and key technologies in the market
• Considerations in formulation design and delivery
• Future outlook
 

9:50 mRNA Therapeutics for Pulmonary Disease

Christian Plank

Christian Plank, Managing Director, CSO, Ethris GmbH
View Bio

• Stabilized non-immunogenic mRNA (SNIM®RNA)
• Formulations for mRNA delivery
• Pulmonary delivery of mRNA
• mRNA transcript therapy for primary ciliary dyskinesia (PCD)
 

10:30 Morning Coffee

11:00 Self-amplifying mRNA vaccines

Jeffrey Ulmer

Jeffrey Ulmer, Head, Preclinical R&D US, GSK
View Bio

• Induction of broad, potent immune responses
• Synthetic methods of manufacture and product characterization
• Facilitate a rapid response to infectious disease outbreaks
• Strategies to streamline vaccines R&D
 

11:40 mRNA Therapeutics for Lung Indications

Klaus Giese

Klaus Giese, CEO, Pantherna Therapeutics GmbH
View Bio

• PTXmRNA® - Novel mRNA molecules
• PTXLNPs® - Novel delivery vehicles
• Lung indications with high medical need
 

12:20 Networking Lunch

13:20 Small activating RNAs(saRNAs) – a novel therapeutic class of oligonucleotides with broad therapeutic potential

David  Blakey

David Blakey, Chief Scientific Officer, MiNA Therapeutics
View Bio

• Description of saRNA technology and broad applicability to a range of therapeutic targets
• Update on MiNA’s lead saRNA product MTL-CEBPA – preclinical and clinical data
• Emerging data on new therapeutic strategies with saRNAs
 

14:00 Development of mRNA Formulations for Clinical Application

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Delivery , BioNTech AG
View Bio

• Application of mRNA for therapeutic intervention
• Nanoparticulate carrier systems for RNA
• Manufacturing and Control of mRNA Nanotherapeutics
 

14:40 Immunotherapeutic RNAs to treat cancer

Steve Pascolo

Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
View Bio

• Optimisation of the production/design of mRNA
• Evaluating the anti-cancer efficacy of immunotherapeutic mRNAs (vaccines and gene therapies)
• Implementation and testing of immunochemotherapeutic RNA
 

15:20 Afternoon Break

15:50 Breaking down the immune barrier in cancer by systemic mRNA immunization

Steven Powell

Steven Powell, CEO, eTheRNA
View Bio

• The importance of Design-of-Experiments for the design of Lipid nanoparticle formulations
• The role of the lipid nanoparticle composition to govern immunogenicity
• The contribution of TriMix in the induction of high T-cell responses
• LNP-formulated mRNA can induce a multifunctional T-cell phenotype
• Systemic immunization leads to a T cell-inflamed tumor microenvironment
 

16:30 Advances in mRNA therapeutics development in the battle against cancer and infectious disease

Surender Vashist

Surender Vashist, RNA Engineering Scientist, Medimmune
View Bio

• A brief update on the regulatory landscape of mRNA therapeutics
• Revisiting the mechanism of action and how this has been manipulated and leveraged
• Optimising formulation and delivery strategies
• Delineating the platforms for immunotherapy and infectious disease
• Analysis of successful clinical outcomes
 

17:10 Chair’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Heinrich Haas

Heinrich Haas, VP RNA Formulation and Drug Delivery , BioNTech AG
View Bio

9:10 MiRNA Therapeutics: From Discovery to the Bedside

Ekkehard Leberer

Ekkehard Leberer, Senior Director, Sanofi
View Bio

• The non-coding genome makes up 98.8% of the human genome. Most of this non-coding genome is transcribed into non-coding RNAs that may play an important role in cellular regulation in health and disease; these non-coding RNAs could be novel targets for future medicines.
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
• The presentation will summarize the opportunities and challenges of developing microRNA-based drugs and will illustrate the successful generation of an anti-fibrotic microRNA-based therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome.
 

9:50 MicroRNA Replacement Therapy: Myth or Reality?

Michel Janicot

Michel Janicot, CDO, InteRNA Technologies BV
View Bio

• miRNAs - Mother Nature has already done most of the job! ...
• miRNAs as novel therapeutic intervention in Oncology
• miRNA replacement therapy (miRNA mimics)
 

10:30 Morning Coffee

11:00 NanoGenics; Using a peptide nanoparticle, LipTide, to develop a siRNA product portfolio

Simon Newman

Simon Newman, CSO, Nanogenics Ltd
View Bio

• How does the peptide nanoparticle, LipTide resemble an artificial virus?
• Delivering siRNA with LipTide across multiple administration routes
• Case study; Targeting the MRTF pathway to develop siRNA anti-fibrotic drugs
 

11:40 Optimising saRNA lipid nanoparticle formulation through a DoE approach on clinically relevant skin explants

Robin Shattock

Robin Shattock, Professor of Mucosal Infection and Immunity, Imperial College London
View Bio

• The promise of self-amplifying mRNA in the field of biotherapeutics: benefits and drawbacks
• The challenges in linear translation from animal to human models
• Utilising Design of Experiments factors of complexing lipid entity, lipid nanoparticle dose, lipid and particle concentration, and ratio of zwitterionic and cationic lipids to optimise saRNA-induced fluorescence in skin explants
• Broad application of the system in molecular and formulation design of clinically relevant oligonucleotide biotherapeutics
 

12:20 Networking Lunch

13:20 MicroRNA inhibitors as therapeutics for common and rare brain diseases

David  Henshall

David Henshall, Professor of Molecular Physiology & Neuroscience, RCSI
View Bio

• Short overview of brain diseases that represent suitable indications for treatment using antagomirs
• Current pipeline of LNA-based oligonucleotides in epilepsy and rare diseases
• Future prospects – delivery challenges, precision targeting using microRNA therapeutics for genetic disease and “network” approaches
 

14:00 The Development of Nucleic Acid Delivery Platforms; a pan-RNA approach

Bo Rode Hansen

Bo Rode Hansen, President & CEO, Genevant Sciences

• At Genevant, we are pursuing a modality agnostic “pan-RNA” approach to develop a diverse pipeline of RNA therapeutics; including delivery of RNAi payloads targeting both viral and endogenous gene targets, and mRNA in vaccine applications.
• Differentiated pan-RNA approach encompassing RNAi, mRNA and gene editing
• Industry-leading lipid nanoparticle (LNP) and ligand conjugate delivery platforms enable “best-fit” modality
 

14:40 Afternoon Tea

15:10 The upcoming regulatory updates in the EU clinical trials arena

Kirsty Wydenbach

Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
View Bio

• Upcoming 2020 regulatory updates affecting EU clinical trials
• Revisiting the regulatory environment and a prescription on how to interact with regulators
• Updates on regulatory expectations on reporting clinical trial data
 

15:50 When RNA therapeutics are biological medicines: regulatory considerations for the EU

Christiane Niederlaender

Christiane Niederlaender, Director, AMBR Consulting Ltd
View Bio

• Classifications of RNA therapeutics within the medicines framework
• RNAs as vaccines and gene therapies and the implications for regulatory assessment and development
• RNAs in CRISPR approaches and the CMC considerations
• Key regulatory issues as highlighted by case studies
 

16:30 Chair’s Closing Remarks and Close of Day Two

+

Exhibitors

Supporting Media Partners

Supporters

Focus Days

Oligonucleotide Delivery Systems Focus Day
Focus Day

Oligonucleotide Delivery Systems Focus Day

Copthorne Tara Hotel
18th February 2020
London, United Kingdom

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

'RNAi therapy in hATTR amyloidosis' by Dr Ali Murad - Alnylam

Download

'Small Activating RNA- From Bench to Bedside' by David Blakey - MINA Therapeutics

Download

'Self amplifying mRNA technology to accelerate vaccines R&D' by Jeffrey Ulmer - GSK

Download

'Enabling Delivery for Genetic Medicines' by Steffen Panzner - Lipocalyx

Download

RNA Therapeutics Programme

Download

2019 RNA Therapeutics Brochure

Download

RNA Therapeutics Attendees 2019

Download

Exhibitors


ChemGenes

Exhibitors
http://www.chemgenes.com

ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.


Thermo Fisher Scientific

Exhibitors
http://www.thermofisher.com/

For more than 40 years, Thermo Fisher Scientific has been a leading supplier of nucleic acid based raw materials, products and service for our customers in diagnostics, therapeutics, pharmaceutical and life science companies. With custom solutions to meet our customers unique quality and regulatory requirements, we help them succeed from development to commercialization. Visit our booth and learn about Thermo Scientific custom and OEM capabilities.

Media Partners


ASD MEDIA

Supporting Media Partners
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


pharmaphorum

Supporting Media Partners
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


Pharma Journalist

Supporting Media Partners
http://www.pharmajournalist.com

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


Gene Therapy Net

Supporting Media Partners
http://www.genetherapynet.com

Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


Pharmalicensing

Supporting Media Partners
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


IPI

Supporting Media Partners
http://www.ipimediaworld.com

IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

Media Partners


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out